Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
FLGT

FLGT - Fulgent Genetics Inc Stock Price, Fair Value and News

19.40USD-0.47 (-2.37%)Market Closed

Market Summary

FLGT
USD19.40-0.47
Market Closed
-2.37%

FLGT Alerts

  • Losses in recent quarter

FLGT Stock Price

View Fullscreen

FLGT RSI Chart

FLGT Valuation

Market Cap

580.5M

Price/Earnings (Trailing)

-3.49

Price/Sales (Trailing)

2.02

EV/EBITDA

-3.75

Price/Free Cashflow

32.35

FLGT Price/Sales (Trailing)

FLGT Profitability

Operating Margin

37.47%

EBT Margin

-58.15%

Return on Equity

-14.7%

Return on Assets

-13.51%

Free Cashflow Yield

3.09%

FLGT Fundamentals

FLGT Revenue

Revenue (TTM)

287.5M

Rev. Growth (Yr)

-2.54%

Rev. Growth (Qtr)

-8.54%

FLGT Earnings

Earnings (TTM)

-166.1M

Earnings Growth (Yr)

12.24%

Earnings Growth (Qtr)

89.48%

Breaking Down FLGT Revenue

Last 7 days

-5.9%

Last 30 days

-10.5%

Last 90 days

-10.5%

Trailing 12 Months

-48.4%

How does FLGT drawdown profile look like?

FLGT Financial Health

Current Ratio

5.09

FLGT Investor Care

Shares Dilution (1Y)

0.75%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024287.5M000
2023364.9M307.4M286.4M289.2M
2022953.4M869.8M702.6M619.0M
2021773.4M909.7M1.0B992.6M
202034.9M43.8M135.1M421.7M
201922.1M25.1M29.8M32.5M
201818.1M18.8M20.0M21.4M
201720.1M20.8M20.3M18.7M
201611.4M13.2M15.3M18.3M
20153.4M5.4M7.5M9.6M
20140001.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Fulgent Genetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 01, 2024
gao hanlin
sold (taxes)
-20,278
20.65
-982
chief scientific officer
Jun 01, 2024
kim paul
sold (taxes)
-32,069
20.65
-1,553
cfo and treasurer
Jun 01, 2024
xie jian
sold (taxes)
-30,541
20.65
-1,479
president and coo
May 23, 2024
xie jian
sold (taxes)
-13,804
21.14
-653
president and coo
May 23, 2024
kim paul
sold (taxes)
-14,142
21.14
-669
cfo and treasurer
May 23, 2024
hsieh ming
sold (taxes)
-44,626
21.14
-2,111
chief executive officer
May 23, 2024
gao hanlin
sold (taxes)
-7,652
21.14
-362
chief scientific officer
May 16, 2024
marsh linda
acquired
-
-
16,000
-
May 16, 2024
groves regina e
acquired
-
-
4,000
-
May 16, 2024
nohaile michael
acquired
-
-
16,000
-

1–10 of 50

Which funds bought or sold FLGT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-9.33
-784
1,384
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-46,000
140,000
-%
May 17, 2024
VIMA LLC
added
2,030
76,339
79,808
0.06%
May 17, 2024
Kozak & Associates, Inc.
unchanged
-
-257
1,463
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-6.31
-177,465
420,481
-%
May 16, 2024
COMERICA BANK
reduced
-13.26
-100,737
187,987
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-53.5
-2,555,800
1,370,360
-%
May 15, 2024
Point72 Asset Management, L.P.
reduced
-45.94
-2,599,400
1,775,060
-%
May 15, 2024
DARK FOREST CAPITAL MANAGEMENT LP
new
-
319,641
319,641
0.05%
May 15, 2024
JANUS HENDERSON GROUP PLC
sold off
-100
-2,868,200
-
-%

1–10 of 43

Are Funds Buying or Selling FLGT?

Are funds buying FLGT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FLGT
No. of Funds

Unveiling Fulgent Genetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 23, 2024
blackrock inc.
12.7%
3,761,878
SC 13G/A
Jan 26, 2023
blackrock inc.
12.0%
3,527,782
SC 13G/A
Jan 20, 2023
blackrock inc.
12.0%
3,527,782
SC 13G
Nov 10, 2022
hsieh ming
29.5%
8,684,102
SC 13D/A
Jan 27, 2022
blackrock inc.
11.5%
3,421,251
SC 13G/A
Jan 26, 2022
blackrock inc.
11.5%
3,421,251
SC 13G/A
Jul 12, 2021
blackrock inc.
10.5%
3,057,315
SC 13G/A

Recent SEC filings of Fulgent Genetics Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading

Peers (Alternatives to Fulgent Genetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
188.8B
23.7B
5.17% 9.67%
42.89
7.95
-8.94% -35.91%
41.8B
3.7B
2.24% 9.78%
48.22
11.22
8.57% 23.94%
38.1B
6.6B
-9.88% 11.43%
30.68
5.78
-6.38% -8.07%
15.4B
9.3B
-1.39% 1.55%
18.19
1.66
-3.29% 6.68%
13.6B
1.2B
8.97% 122.00%
-37.24
11.26
39.26% 33.08%
12.2B
2.0B
3.72% 84.36%
39.08
6.22
25.57% 21.62%
10.9B
4.1B
-6.38% 2.81%
24.62
2.66
0.49% -10.45%
MID-CAP
7.9B
2.5B
-24.30% -55.03%
-32.86
3.11
15.21% 53.51%
3.9B
603.7M
32.67% -15.43%
-8.37
6.39
25.21% 30.68%
3.7B
929.2M
32.48% -13.74%
2.4K
3.96
28.93% 111.61%
SMALL-CAP
761.5M
275.1M
2.07% 82.89%
-4.16
2.77
-13.93% -126.97%
84.8M
31.1M
-2.54% -87.84%
-1.1
2.73
0.95% 19.75%
24.3M
9.0M
-35.42% -38.41%
-1.65
2.7
4.46% 45.80%
521.9K
5.5M
-83.77% -62.12%
-0.04
0.09
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Fulgent Genetics Inc News

Latest updates
MarketBeat33 minutes ago
Seeking Alpha06 Jun 202403:36 pm
Zacks Investment Research03 May 202407:00 am
Business Wire03 May 202407:00 am

Fulgent Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Revenue-8.5%64,48570,50584,68767,85366,16867,704105,655125,341222,805320,268251,671227,868153,616359,429294,978101,71617,2657,7538,38710,3478,424
Cost Of Revenue-6.4%42,38145,27644,84347,28147,35754,71759,56060,065-77,72562,13443,46635,85874,07551,77226,2617,7174,0573,6343,8853,620
Gross Profit-12.4%22,10425,22939,84420,57218,81112,98746,09565,276-242,543189,537184,402117,758285,354243,20675,4559,5483,6964,7536,4624,804
Operating Expenses-75.1%43,902176,35039,63040,37043,63549,53945,74352,482-40,61038,67725,12918,86018,43217,29711,9326,9085,6105,1624,9534,509
  S&GA Expenses-14.4%8,98910,50010,16110,72310,08310,2539,85910,866-7,9408,2006,0125,2195,0085,0815,0143,2601,5971,6351,6871,304
  R&D Expenses-4.3%11,43411,95210,0149,6929,7828,5097,5076,905-5,9897,4646,0215,3125,4224,5763,1771,8491,9781,7951,7441,574
EBITDA Margin4.0%-0.49*-0.51*-------------------
Interest Expenses-439--------------------
Income Taxes97.0%-327-10,86720,326-3,100-5,200-9,3864142,653-48,40047,14837,54523,58966,51358,57114,526-59934.00-38.0061.007.00
Earnings Before Taxes90.2%-14,173-145,1966,860-14,700-21,049-33,4621,75713,752-201,978150,825159,76999,502267,204226,49863,9442,915-1,673-1601,698487
EBT Margin3.4%-0.58*-0.60*-0.22*-0.22*-0.11*0.30*0.52*0.67*0.70*0.64*0.68*0.73*0.72*--------
Net Income89.5%-13,462-127,968-13,107-11,590-15,340-23,8321,71911,099-153,557104,339122,52279,812200,691166,30746,6383,321-1,956-2961,462331
Net Income Margin0.5%-0.58*-0.58*-0.22*-0.16*-0.07*0.23*0.39*0.50*0.53*0.48*0.51*0.55*0.54*--------
Free Cashflow-72.9%3,21011,8275,317-2,407-9,94128,48515,3417,868183,051183,05171,103148,79973,176--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.4%1,2301,2351,3581,3551,3771,3861,4061,4621,4661,2791,2051,05099970024796.0089.0089.0061.0056.0056.00
  Current Assets-23.9%38750855052858162869767576561262356765952419641.0037.0037.0039.0035.0036.00
    Cash Equivalents-43.9%55.0097.0084.0058.0066.0080.0016913935316521510015187.0053.002.009.0012.0021.009.005.00
  Net PPE3.9%87.0083.0085.0088.0079.0081.0082.0086.0069.0062.0060.0051.0047.0040.0017.006.006.006.006.006.006.00
  Goodwill0%22.0022.0014214214314312012151.0051.0049.0023.00---------
Liabilities1.2%10310297.0091.0010811612415115311316012919813160.009.008.006.007.005.006.00
  Current Liabilities4.0%76.0073.0061.0065.0082.0088.0010312814210514712219713058.007.006.004.004.003.003.00
Shareholder's Equity-0.5%1,1301,1361,2591,2631,2691,2701,2811,3111,3131,1661,04492180256918787.0081.0083.0055.0051.0050.00
  Retained Earnings-2.1%620633761774786801825823812658553431351151-15.43-62.06-65.39-63.43-63.13-64.59-64.93
  Additional Paid-In Capital1.9%511502514506496487478504507502484482451418202148147146117116115
Shares Outstanding0.8%30.0030.0030.0030.0030.0029.0030.0030.0030.0029.0030.0029.00---------
Minority Interest-17.1%-3.30-2.813.004.004.003.004.006.007.007.008.008.00---------
Float----629---978---1,600---191---39.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-51.3%7,26614,93310,2409,737-7,90733,20720,77611,126188,41177,086152,20176,111233,179134,2569,415-4,4091,366-1163,9036751,055
  Share Based Compensation0.8%11,51811,43210,90210,32310,26510,0228,9728,0305,6165,0204,3743,5262,9623,0033,1501,080924938951737583
Cashflow From Investing-294.4%-47,18624,27020,078-1,096-4,354-92,59944,289-213,692688-140,259-34,793-155,005-216,491-318,767-1,404-2,405-3,862-36,0796,3443,211-2,522
Cashflow From Financing89.2%-2,807-25,951-4,474-16,259-1,101-29,593-35,462-11,152-93413,154-2,98927,89347,347218,90342,571-59.00-16427,6391,1275.004.00
  Buy Backs-99.0%22522,8622,200--28,80234,70210,577----51316.00--46.00----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

FLGT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 64,485,000$ 66,168,000
Cost of revenue42,381,00047,357,000
Gross profit22,104,00018,811,000
Operating expenses:  
Research and development11,434,0009,782,000
Selling and marketing8,989,00010,083,000
General and administrative21,489,00021,802,000
Amortization of intangible assets1,990,0001,968,000
Total operating expenses43,902,00043,635,000
Operating loss(21,798,000)(24,824,000)
Interest and other income, net7,625,0003,775,000
Loss before income taxes(14,173,000)(21,049,000)
Benefit from income taxes(327,000)(5,200,000)
Net loss from consolidated operations(13,846,000)(15,849,000)
Net loss attributable to noncontrolling interests384,000509,000
Net loss attributable to Fulgent$ (13,462,000)$ (15,340,000)
Net loss per common share attributable to Fulgent:  
Basic$ (0.45)$ (0.52)
Diluted$ (0.45)$ (0.52)
Weighted-average common shares:  
Basic29,76929,536
Diluted29,76929,536

FLGT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 54,677$ 97,473
Marketable securities251,018326,681
Trade accounts receivable, net of allowance for credit losses of $25,831 and $25,22652,06051,132
Other current assets28,75432,559
Total current assets386,509507,845
Marketable securities, long-term540,495423,571
Redeemable preferred stock investment20,43820,438
Fixed assets, net86,72383,464
Intangible assets, net140,989143,053
Goodwill, net22,05522,055
Other long-term assets32,67634,902
Total assets1,229,8851,235,328
Current liabilities  
Accounts payable19,61615,360
Accrued liabilities25,91830,737
Customer deposit27,24022,700
Contract liabilities2,7622,874
Notes payable, current portion4131,183
Other current liabilities0164
Total current liabilities75,94973,018
Deferred tax liabilities7,4057,962
Unrecognized tax benefits5,9785,978
Other long-term liabilities13,90715,084
Total liabilities103,239102,042
Commitments and contingencies (Note 8)
Stockholders’ equity  
Common stock, $0.0001 par value per share, 50,000 shares authorized, 32,664 and 32,416 shares issued, respectively, and 29,890 and 29,653 shares outstanding, respectively33
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding
Additional paid-in capital511,329501,718
Accumulated other comprehensive (loss) income(1,102)1,205
Retained earnings619,713633,175
Total Fulgent stockholders' equity1,129,9431,136,101
Noncontrolling interest(3,297)(2,815)
Total stockholders’ equity1,126,6461,133,286
Total liabilities and stockholders’ equity$ 1,229,885$ 1,235,328
FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
 CEO
 WEBSITEfulgentgenetics.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES1012

Fulgent Genetics Inc Frequently Asked Questions


What is the ticker symbol for Fulgent Genetics Inc? What does FLGT stand for in stocks?

FLGT is the stock ticker symbol of Fulgent Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulgent Genetics Inc (FLGT)?

As of Wed Jun 12 2024, market cap of Fulgent Genetics Inc is 594.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers. The fair value of Fulgent Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fulgent Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FLGT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fulgent Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether FLGT is over valued or under valued. Whether Fulgent Genetics Inc is cheap or expensive depends on the assumptions which impact Fulgent Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FLGT.

What is Fulgent Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, FLGT's PE ratio (Price to Earnings) is -3.58 and Price to Sales (PS) ratio is 2.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FLGT PE ratio will change depending on the future growth rate expectations of investors.